COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 85: Line 85:
*'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]'''
*'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]'''
'''Infectious diseases and COVID-19'''
'''Infectious diseases and COVID-19'''
* [[User:Zaida Obeidat|User:Zaida Obeidat, M.D.]]
* [[User:Zaida Obeidat|Zaida Obeidat, M.D.]]
'''[[COVID-19 medical therapy]]
'''[[COVID-19 medical therapy]]
* [[User:Sara Zand|Sara Zand, M.D.]]
* [[User:Sara Zand|Sara Zand, M.D.]]
'''[[COVID-19 other diagnostic studies]]
'''[[COVID-19 other diagnostic studies]]
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]]

Revision as of 21:33, 12 August 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Constant Update of the Page

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members